康希諾AH股齊升 吸入式新冠疫苗臨牀試驗年內肯定會有結果
格隆匯4月20日丨康希諾生物AH股同步拉昇,AH股均漲超5%,A股報390元,H股報304.8港元。據澎湃,在博鰲亞洲論壇2021年年會期間,康希諾生物聯合創始人、董事長兼首席執行官宇學峯在接受採訪時,透露了吸入式新冠疫苗的最新研究進展。“我們先把臨牀試驗做完,年內肯定會有結果,我也很有信心,(吸入式疫苗)是個很好的途徑”。宇學峯表示,最好的疫苗應該是能夠快速生效、容易獲得、容易使用,因此康希諾開發了單劑疫苗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.